2025
A Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in Children
McGovern S, Johnson J, Luo D, Nguyen K, McAleer M, Paulino A, Grosshans D, Baxter P, Zaky W, Thall P, Mahajan A. A Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in Children. International Journal Of Radiation Oncology • Biology • Physics 2025, 121: e13-e14. DOI: 10.1016/j.ijrobp.2024.11.049.Peer-Reviewed Original ResearchDose-volume constraintsSymptomatic brain necrosisRecurrent brain tumorsBrain tumorsBrain necrosisPrimary endpointDose constraintsProton therapyProspective studyRecurrent pediatric brain tumorsMedian overall survivalMedian prescription doseCourse of radiationResults Median ageTreated with radiationPediatric brain tumorsPrimary brain tumorProgression of diseaseBrain reirradiationDosimetric guidelinesDose escalationPrescription doseOverall survivalMedian intervalProspective trials
2023
Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma.
Kurz S, Zan E, Cordova C, Troxel A, Barbaro M, Silverman J, Snuderl M, Zagzag D, Kondziolka D, Golfinos J, Chi A, Sulman E. Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma. Clinical Cancer Research 2023, 30: 680-686. PMID: 38048045, DOI: 10.1158/1078-0432.ccr-23-2533.Peer-Reviewed Original ResearchConceptsProgression-free survivalSomatostatin receptor type 2PFS-6Stable diseaseOverall survivalIntracranial meningiomasSingle-arm phase II clinical studyMedian progression-free survivalPhase II clinical studyImaging biomarkersCourse of radiationReceptor type 2Multicenter clinical trialMacdonald criteriaMedian OSRadiographic responseProgressive meningiomasTumor measurementsTumor resectionMedian agePrimary endpointRadiotherapeutic interventionSecondary endpointsMedical therapyAdult patients
2022
CTNI-57. RADIONUCLIDE THERAPY WITH 177LU-DOTATATE (LUTATHERA) IN ADULTS WITH ADVANCED INTRACRANIAL MENINGIOMA - INTERIM ANALYSIS RESULTS OF A SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE II STUDY
Kurz S, Zan E, Cordova C, Barbaro M, Troxel A, Silverman J, Snuderl M, Zagzag D, Golfinos J, Kondziolka D, Sulman E. CTNI-57. RADIONUCLIDE THERAPY WITH 177LU-DOTATATE (LUTATHERA) IN ADULTS WITH ADVANCED INTRACRANIAL MENINGIOMA - INTERIM ANALYSIS RESULTS OF A SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE II STUDY. Neuro-Oncology 2022, 24: vii85-vii85. DOI: 10.1093/neuonc/noac209.322.Peer-Reviewed Original ResearchSomatostatin receptor 2Progression-free survivalPhase II studyPFS-6Interim analysis resultsII studyIntracranial meningiomasClinical trialsMulticenter phase II studySomatostatin receptor 2 expressionInterim analysisPET-MRITreatment-limiting toxicityAggressive clinical courseCourse of radiationPET-MR imagingMethylation subclassesRadiotherapeutic optionsStable diseaseProgressive meningiomasOverall survivalNeuroendocrine tumorsSSTR2 expressionTumor measurementsTumor resection
2020
CTNI-53. SINGLE ARM, OPEN-LABEL, MULTICENTER PHASE II STUDY OF THE RADIONUCLIDE 177LU-DOTATATE (LUTATHERA) IN ADULTS WITH ADVANCED INTRACRANIAL MENINGIOMA
Kurz S, Zan E, Gurewitz J, Cordova C, Troxel A, Sawaged Z, Sevillano-Torres H, Silverman J, Snuderl M, Zagzag D, Golfinos J, Kondziolka D, Sulman E. CTNI-53. SINGLE ARM, OPEN-LABEL, MULTICENTER PHASE II STUDY OF THE RADIONUCLIDE 177LU-DOTATATE (LUTATHERA) IN ADULTS WITH ADVANCED INTRACRANIAL MENINGIOMA. Neuro-Oncology 2020, 22: ii54-ii55. PMCID: PMC7651467, DOI: 10.1093/neuonc/noaa215.219.Peer-Reviewed Original ResearchSomatostatin receptor 2Somatostatin receptor 2 expressionProgression-free survivalPhase II studyStandardized uptake valueIntracranial meningiomasPFS-6II studyBackground MeningiomasProgressive diseaseTreatment responseMulticenter phase II studyPET-MRIFunctional treatment responseCourse of radiationPrimary intracranial neoplasmsPET-MR imagingMethylation subclassesRadiotherapeutic optionsStable diseaseCTCAE gradeProgressive meningiomasOverall survivalNeuroendocrine tumorsSSTR2 expressionBeyond reirradiation: Efficacy and safety of three or more courses of radiation for head and neck malignancies
Xu AJ, Luo L, Leeman JE, Romesser PB, Spielsinger D, Sabol C, Waldenberg T, Brinkman T, Riaz N, McBride S, Kang J, Lee N, Tsai CJ. Beyond reirradiation: Efficacy and safety of three or more courses of radiation for head and neck malignancies. Clinical And Translational Radiation Oncology 2020, 23: 30-34. PMID: 32382663, PMCID: PMC7200775, DOI: 10.1016/j.ctro.2020.04.009.Peer-Reviewed Original ResearchCourse of radiationMedian local recurrence-free survivalNeck regionLocal recurrence-free survivalGrade 5 toxicityMedian overall survivalRecurrence-free survivalSingle-institution databaseFree survivalOverall survivalSelect patientsSystemic therapyNeck malignanciesRecurrent headSignificant morbiditySubsequent therapyNeck cancerMulti-disciplinary teamGrade 3Institution's databasePatientsLocal controlReirradiationTreatment planMultiple courses
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply